Gene ID number
7048
Modification site(s)
Tyr259
Swiss Prot
P37173
French translation
anticorps
Subcellular location
Cytoplasm
Immunogen range
250-270/567
Concentration
1ug per 1ul
Conjugation
Unconjugated
Target Antigen
TGFBR2 Tyr259
Modification(s)
Phosphorylation
Cross reactivity
Human, Mouse, Rat
Also known as
TGFBR2 Tyr259 PAb
Category
Primary Antibodies
Clonality
Polyclonal antibody
Clone number
Polyclonal antibody
Tested Applications
WB, IHC-P, IF(IHC-P)
Long name
TGFBR2 Tyr259 Primary Polyclonal Antibody
Purification method
This antibody was purified via Protein A.
Recommended dilutions
WB(1:100-1000), IHC-P(1:100-500), IF(IHC-P)(1:50-200)
Specificity
This is a highly specific antibody against TGFBR2 Tyr259.
Cross reactive species details
Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.
Source
KLH conjugated synthesised phosphopeptide derived from human TGF beta Receptor II around the phosphorylation site of Tyr259
Storage conditions
Keep the antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store at -20°C for up to 1 year.
Properties
If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.
Synonym names
AAT3; FAA3; LDS2; MFS2; RIIC; LDS1B; LDS2B; TAAD2; TGFR-2; TGFbeta-RII; TGF-beta receptor type-2; TGF-beta type II receptor; Transforming growth factor-beta receptor type II; TGF-beta receptor type II; TbetaR-II; TGFBR2
Background of the target antigen
Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways.